DANISH BIO – DANSK BIOTEK organizes four major plenary meetings for our members throughout the year to increase our members' knowledge regarding specific biotech topics and to facilitate networking. The events usually take place in February, May, September and November.

We also organize approximately four "saloon" meetings annually. They are small, intimate, "meet the expert" meetings with typically 6-20 participants advocating more in-depth discussion and knowledge-sharing on specific themes.

News

FDA Approves Y-mAbs’ DANYELZA® (naxitamab-gqgk) for the Treatment of Neuroblastoma 27 November 2020

Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical... Read more

Y-mAbs Announces Update on Omburtamab in DIPG 19 November 2020

Y-mAbs Therapeutics, Inc. today announced a clinical update on omburtamab for the treatment of diffuse... Read more

Damvad Analytics Report on Growth Opportunities for the Life Science Industry 11 November 2020

As mentioned in a previous Newsletter, DANISH BIO – DANSK BIOTEK has joined the newly established Genstartsteam... Read more

IO Biotech Announces First Patient Dosed in Phase 2 Trial in Head and Neck Cancer Conducted in a Collaboration with Cliniques Universitaires Saint-Luc in Belgium 04 November 2020

IO Biotech, a clinical-stage biopharmaceutical company developing novel, immune modulating anti-cancer... Read more

Y-mAbs to Announce Third Quarter 2020 Financial and Operating Results on November 5, 2020 29 October 2020

Y-mAbs Therapeutics, Inc. today announced that it will report its financial results for the third quarter... Read more

EATRIS SURVEY mapping patient stratification strategies currently undertaken by industry 27 October 2020

As a member of DANISH BIO – DANSK BIOTEK you are invited to participate in this survey mapping patient... Read more

Y-mAbs Announces FDA Clearance of IND for its Lutetium-177 Labeled Omburtamab Antibody for Adult Indications 26 October 2020

Y-mAbs, a late-stage clinical biopharmaceutical company focused on the development and commercialization... Read more

Y-mAbs Announces Update on Naxitamab and Omburtamab in Neuroblastoma 16 October 2020

Y-mAbs, a late-stage clinical biopharmaceutical company focused on the development and commercialization... Read more

Berlingske insert on Biotech featuring DANISH BIO – DANSK BIOTEK (in Danish) 12 October 2020

Read the entire insert here and the article with Hans Shambye here. >>

Copyright 2020 DANISH BIO – DANSK BIOTEK. All rights reserved.

created by: Mastafu Design